Singtel Innov8

Singtel Innov8 is the corporate venture capital fund of Singtel, the Singapore-based telecommunications incumbent with significant operations across Australia, India, Indonesia, the Philippines, and Thailand. Stage focus is Series A through Series C with checks in the $1M to $5M range, and AI is not flagged as a primary focus. Healthcare interest expresses through digital health and healthcare software, with the strategic logic flowing from Singtel’s broader interest in next-generation digital services that can be distributed through its consumer and enterprise channels across the region. The right founder for Innov8 is a Southeast Asian or globally relevant healthcare operator with real revenue and scaled traction, whose product creates strategic value to Singtel’s distribution channels, ranging from telehealth services bundled with mobile plans to enterprise health benefits sold to Singtel’s corporate customers and 5G-enabled clinical applications. The wrong founder is a deep medtech or therapeutics team, an early-stage seed company, or a healthcare business with no telecom or distribution relevance. Intro paths run through Singtel’s enterprise sales organization and corporate development team, frequent co-investors and follow-on partners including Vertex Ventures, Heritas Capital, EDBI, Wavemaker Partners, and Singapore-based growth funds, and through Innov8’s existing portfolio CEOs many of whom are publicly active. Direct outreach is acknowledged but conversion is materially better through institutional referral or strategic operator connection within the Singtel orbit. In the pitch, lead with the strategic angle: how does your healthcare business create incremental value for a major telecom operator, whether through subscriber stickiness, enterprise health benefits, network-enabled clinical applications, or data-driven insurance distribution. Show real revenue, retention metrics, and a credible plan to use Singtel’s distribution channels in Singapore, Australia, India, or Indonesia for accelerated scaling. Be specific about regulatory posture in your primary markets and your data architecture given the cross-border dynamics. Caveats are the standard CVC ones, including the inherent tensions of corporate venture and the reality that Singtel’s strategic priorities can shift with leadership changes. The fit is good for healthcare businesses with credible distribution synergies; for businesses without that wedge, the fit is forced.